oral birth control and semaglutide (Ozempic, Wegovy) control: What to know Semaglutide, a Once-Weekly Human GLP-1

While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved

For more detailed advice on maintaining your weight after Wegovy, read our Wegovy Maintenance Guide

Additionally, dehydration reduces the kidney's ability to dilute waste products effectively, further contributing to odor intensity

Further research is needed to fully understand this connection

That affects the outcomes of the clinical trial and affects accrual and how we manage those patients on study

Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: A narrative review